Author

Bao Xue

First Affiliated Hospital of Guangzhou Medical University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Approach:graph neural network· 1 Assay:proteomics· 1

Frequent Co-Authors

Anqi ZhouiD· 2 shared Hongming CheniD· 2 shared Jielin TangiD· 2 shared Jinpeng Zhong· 2 shared Jinsai ShangiD· 2 shared Jiyun Zhang· 2 shared Minxian Dai· 2 shared Miru Tang· 2 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Anqi ZhouORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19

Yongzhi Lu, Qi Yang, Ting Ran, Guihua Zhang, Weifeng Li, Peiqi Zhou, Jielin Tang, Minxian Dai, Jinpeng Zhong, Hua Chen, Pan He, Anqi Zhou, Bao Xue, Jiayi Chen, Jiyun Zhang, , Jinsai Shang

The paper identifies a potent orally bioavailable SARS-CoV-2 PLpro inhibitor with in vitro and in vivo antiviral activity against SARS-CoV-2 and related coronaviruses.

Nature Communications · Nov 23, 2024Peer-reviewedMicrobiology

Discovery of resistance-resilient quinoline papain-like protease inhibitors through topology-constrained molecular generative design

Yongzhi Lu, Ting Ran, Qi Yang, Guihua Zhang, Jiayi Chen, Peiqi Zhou, Wenqi Li, Minyuan Xu, Jielin Tang, Minxian Dai, Jinpeng Zhong, Hua Chen, Pan He, Anqi Zhou, Bao Xue, , Jinsai Shang

This paper discovers a novel quinoline-based PLpro inhibitor, GZNL-2016, that remains effective against drug-resistant SARS-CoV-2 variants like Omicron BA.5 and XBB.1.

bioRxiv · Sep 7, 2024 · PreprintMicrobiology